Roche announced today that it plans to invest up to $550 million to expand its continuous glucose monitoring (CGM) site in the U.S. The company plans to invest in its Diagnostics site in Indianapolis in a project that runs through 2030. It expects to make the site — which serves as the North American headquarters […]
Diagnostics
Satio, Nanowear collab to bring AI-powered biomarkers to drug delivery
Satio and Nanowear today announced that they partnered to advance patient-friendly, home-based diagnostic and therapeutic care. The collaboration aims to integrate Nanowear’s at-home AI-based nanotechnology biomarker diagnostic platform with Satio’s at-home blood draw diagnostics and drug delivery systems/patches. This would combine time-synchronous, in vivo and in vitro diagnostics for precision therapeutics and individualized AI-based risk […]
Nanowear enters CGM licensing, data partnership with Dexcom
Nanowear announced today that it entered into a partnership with Dexcom to ingest glucose data from its latest continuous glucose monitors (CGMs). The partnership will see Nanowear’s SimpleSense nanotechnology-enabled wearable, mobile and software diagnostics platform take data from the Dexcom G7 CGM, combining continuous glucose readings, blood pressure, ECGs, lung volume, respiration and hemodynamics. This […]
Orange Biomed to showcase microfluidic-based A1C test
Orange Biomed announced today that it plans to showcase its microfluidic-based A1C test at the 2024 Diabetes Technology Meeting. The company intends to present research for the device during the event’s Startup Showcase next month. It developed the pocket-sized, single-cell, micro-electro-mechanical A1C analysis device, agnostic to hemoglobin variants, to deliver faster, more reliable results for […]
CorFlow Therapeutics raises $48.5M for diagnostic, drug delivery platform
CorFlow Therapeutics announced today that it raised €44 million ($48.5 million) to support its novel diagnostic and drug delivery platform. Broadview Ventures and Panakes Partners led the financing round. 415 Capital, Merieux Equity Partners, Merieux Equity Partners, Laerdal Million Lives Fund, Wellington Partners, M&L Investments, Unorthodox Ventures, KOFA Healthcare and Monte Carlo Capital also participated. […]
Know Labs data backs non-invasive sensor for glycemic status screening
Know Labs (NYSE:KNW) today shared new data highlighting the use of its non-invasive blood glucose sensor in glycemic status monitoring. The Seattle-based company published its peer-reviewed study in Diabetes Technology & Therapeutics Journal. The published results demonstrated that Know Labs’ proprietary non-invasive radiofrequency (RF) dielectric sensor and trade-secret machine learning (ML) algorithms correctly classified an individual’s glycemic […]
Abbott wins FDA clearance for its Lingo OTC glucose monitor
Abbott (NYSE: ABT) has secured a 510(k) clearance from the FDA for its over-the-counter Lingo glucose-monitoring biowearable. The clearance came on May 29, according to a listing on the FDA’s website. An Abbott spokesperson said the company was aware of the clearance and would provide more details later. FDA clearance for Abbott’s Lingo comes more […]
Orange Biomed unveils at-home A1c test in the U.S.
Orange Biomed announced today that it commenced a U.S. launch as it looks to fill testing gaps for pre-diabetes and diabetes. Seoul, South Korea–based Orange Biomed operates out of Research Triangle Park, North Carolina in the U.S. The company currently has ongoing studies for its OBM rapid A1c test. It designed the glycated hemoglobin analyzer […]
Researchers tout AI-based diabetes onset prediction method
Scientists at Klick Applied Sciences say they discovered a way to use a continuous glucose monitor (CGM) as a diabetes screening tool. The scientists determined that they can use artificial intelligence (AI) to screen and prevent the chronic health condition. They used machine learning and 12 hours of data from CGMs to determine whether a […]
Dexcom focuses on early diabetes diagnosis as COVID links emerge
New evidence is showing that COVID-19 may increase a person’s risk of diabetes, but it could be years until we know for sure. In the meantime, Dexcom (Nasdaq:DXCM) is getting ready, VP of Global Clinical Initiatives Tomas Walker said. Walker recently spoke with Medical Design & Outsourcing to discuss the San Diego-based diabetes device developer’s proactive approach […]
